Lupin Spins Out Oncology Assets to Kaveri Therapeutics for Global Clinical Push
Event summary
- Lupin spins out two oncology programs (LNP7457 and LNP8701) to Kaveri Therapeutics, retaining a significant equity stake.
- Kaveri will seek additional capital to fund global clinical trials for the PRMT5 and SOS1-targeting therapies.
- Both programs reported positive data at ASCO meetings in 2025 and 2026.
- Kaveri operates independently under leadership of CEO Kristi Jones and CMO Dr. Robert Pierce.
The big picture
This move reflects Lupin's strategic pivot to streamline its oncology portfolio while maintaining exposure through equity participation. The spin-out allows Kaveri to focus exclusively on advancing these targeted therapies, potentially accelerating development timelines. This aligns with broader industry trends of specialized biotech companies driving innovation in oncology through focused clinical strategies.
What we're watching
- Capital Raising Success
- Whether Kaveri can secure sufficient additional funding to advance both programs through global clinical trials.
- Clinical Development Pace
- The speed at which Kaveri progresses LNP7457 and LNP8701 through trials, particularly in solid tumors like lung and pancreatic cancer.
- Strategic Focus Shift
- How this spin-out affects Lupin's broader oncology strategy and whether it signals a shift toward more focused investments in high-potential assets.
Related topics